ApoA-I-Directed Therapies for the Management of Atherosclerosis.

about

Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.Pharmacological Intervention to Modulate HDL: What Do We Target?

P2860

Q45874236-7CF38AD3-134A-4526-AAD3-656B2F842102 Q49554117-D9507B28-5978-4E22-B804-DFA2C0321EFC

P2860

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

Item

http://www.wikidata.org/entity/Q38579703

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

@en

type

Item

label

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

@en

prefLabel

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

@en

P1476

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

@en

P2093

John S Millar

http://www.w3.org/2001/XMLSchema#string

Marina Cuchel

http://www.w3.org/2001/XMLSchema#string

P2860

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Effects of torcetrapib in patients at high risk for coronary events

In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.

Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.

P2888

s11883-015-0539-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11883-015-0539-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013252698

http://www.w3.org/2001/XMLSchema#string

P698

26335143

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

about

P2860

P2860

ApoA-I-Directed Therapies for the Management of Atherosclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921